Restimulation of tumour-specific immunity in a patient with AML following injection with B7-1 positive autologous blasts

Leukemia Research

Volumn 27, Issue 11, 2003, Pages 1051-1061

  Hicks, Christine ^a   Cheung, Carol ^a   Lindeman, Robert ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Blasts; CD80; Costimulation; CTL; Immunogenic

Indexed keywords

B7 ANTIGEN; CYTARABINE; ETOPOSIDE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; AUTOTRANSPLANTATION; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL TRIAL; COCULTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN BIOPSY; T LYMPHOCYTE; VACCINATION;

EID: 0037677437     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00058-4     Document Type: Article

References (42)

1. Green W.R. Cell surface expression of cytotoxic T lymphocyte-defined AKR/gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic cells. J. Immunol. 131:1983;3078-3084.
2. Knoth A., Wolfel T., Klehmann E., Boon T., Meyer zum Buschenfelde K.H. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. U.S.A. 86:1989;2804-2808.
3. Chen L.P., Linsley P.S., Hellstrom K.E. Costimulation of T-cells for tumor-immunity. Immunol. Today. 14:1993;483-486.
4. Galea-Lauri J., Farzaneh F., Gaken J. Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther. 3:1996;202-214.
5. Hirst W.J.R., Buggins A., Darling D., Gaken J., Farzaneh F., Mufti G.J. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther. 4:1997;691-699.
6. Zheng Z., Takahashi M., Aoki S., Toba K., Liu A., Osman Y.et al. Expression patterns of costimulatory molecules on cells derived from human haematological malignancies. J. Exp. Clin. Cancer Res. 17:1998;251-258.
7. Chen L.P., Ashe S., Brady W.A., Hellstrom I., Hellstrom K.E., Ledbetter J.A.et al. Costimulation of anti-tumour immunity by the B7 counter receptor for the lymphocyte-T molecules CD28 an CTLA-4. Cell. 71:1992;1093-1102.
8. Townsend S.E., Allison J.P. Tumor rejection after direct co-stimulation of CD8+ T-cells by B7-transfected melanoma-cells. Science. 259:1993;368-370.
9. Matulonis U.A., Doisu C., Lamont C., Freeman G.J., Mauch P., Nadler L.M.et al. Role of B7.1 in mediating an immune response to myeloid leukemia cells. Blood. 85:1995;2507-2515.
10. Danussi-Joannopoulos K., Weistein H., Nickerson P.N., Strom T.B., Burakoff S.J., Croop J.M.et al. Irradiated B7.1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood. 87:1996;2938-2946.
11. Johnston J.V., Malacko A.R., Mizuno M.T., McGowan P., Hellstrom I., Hellstrom K.E.et al. B7-CD28 costimulation unveils the heirachy of tumor epitopes recognised by major histocompatability complex class I-restricted CD8(+) cytolytic T lymphocytes. J. Exp. Med. 183:1996;791-800.
12. Buggins A.G., Lea N., Gaken J., Darling D., Farzaneh F., Mufti G.J.et al. Effect of costimulation and the microenviromnment on antigen presentation by leukemic cells. Blood. 94:1999;3479-3490.
13. Mazzocchini A., Melani C., Rivoltini L., Castelli C., Del Vecchio M., Lombardo C.et al. Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol. Immunother. 50:2001;199-211.
14. Fenton R.T., Sznol M., Luster D.G., Taub D.D., Longo D.L. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. Hum. Gene Ther. 6:1995;87-106.
15. Gaken J.A., Hollingsworth S.J., Hirst W.J.R., Buggins A.G., Galea-Lauri J., Peakman M.et al. Irradiated NC adenocarcinoma cells transduced with both B7.1 and IL-2 induce CD4(+)-mediated rejection of established tumors. Hum. Gene Ther. 8:1997;477-488.
16. Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future strategies. Leukemia. 13:1993;1175-1187.
17. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organisation classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
18. Hicks C., Keoshkerian E., Gaudry L., Lindeman R. B7-1 (CD80) expression on human acute myeloid leukaemia cells cultured with GM-CSF, IL-3 and IL-6. Cancer Immunol. Immunother. 50:2001;173-180.
19. Hicks C., Keoshkerian E., Ffrench R., Lindeman R. Adenoviral mediated interleukin-2 gene transfer to human long-term bone marrow stromal cultures. Cancer Biother. Biopharm. 16:2001;537-542.
20. Brenner M.K., Heslop H., Krance R., Horowitz M., Strother D., Nuchtern J.et al. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum. Gene Ther. 11:2000;1477-1488.
21. Wilmott R.W., Whitsett J.A., Trapnell B.C. Principal investigators. A phase I study of gene therapy of cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. Fed. Reg. 58:1993;8500-8501.
22. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemic cell line with positive Philadelphia chromosome. Blood. 45:1975;321-324.
23. Weidmann E., Breiger J., Jahn B., Hoelzer D., Bergmann L., Mitrou P.S. Lactate dehydrogenous-release assay: a reliable nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann. Haematol. 70:1995;153-158.
24. van Broekhoven C., Altin J.G. A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. Int. J. Cancer. 98:2002;63-72.
25. Gillis S., Gillis A.E., Henney C.S. Monoclonal antibody directed against interleukin 2. I. Inhibition of T lymphocyte mitogenesis and the in vitro differentiation of alloreactive cytolytic T cells. J. Exp. Med. 154:1981;983-988.
26. Forni G., Fujiwara H., Martino F., Hamaoka T., Jemma C., Caretto P.et al. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphocytes for experimental and clinical immunotherapy. Cancer Metastasis Rev. 4:1988;289-309.
27. Osanto S., Schiphorst P.P., Weijl N.I., Dijkstra N., Van Wees A., Brouwenstein N.et al. Vaccination of melanoma patients with allogeneic, genetically modified interleukin 2-producing melanoma cell lines. Hum. Gene Ther. 11:2000;739-750.
28. Schmidinger M., Steger G., Wenzel C., Locker G.J., Brodowicz T., Budinsky A.C.et al. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Australian Renal Cell Carcinoma Study Group. Cancer Immunol. Immunother. 49:2000;395-400.
29. Simons J.W., Mikhals B. Ex vivo gene therapy using cytokine transduced tumor vaccines: molecular and clinical pharmacology. Semin. Oncol. 25:1998;661-676.
30. Salvadori S., Gansbacher B., Wernick I., Tirelli S., Zier K. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum. Gene Ther. 6:1995;1299-1306.
31. Nouri A.M.E., Dorey E., Davis C.L., Rohatin A., Lister T.A., Oliver R.T.D. Generation of cytotoxic T lymphocytes from peripheral blood of leukemic patients. Cancer Immunol. Immunother. 37:1993;47-53.
32. Unanue E.R., Allen M. The basis for the immunoregulatory role of macrophages and other accessory cells. Science. 236:1987;551-557.
33. Fleisher B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature (London). 308:1984;365-367.
34. Erb P., Grogg D., Troxler M., Kennedy M., Fluri M. CD4+ T cell-mediated killing of MHC class II-positive antigen-presenting cells. I. Characterisation of target cell recognition by in vivo or in vitro activated CD4+ killer T cells. J. Immunol. 144:1990;790-795.
35. Kabelitz D., Brucker C., Wagner H., Fleischer B. A previously unrecognised large fraction of cytotoxic lymphocyte precursors is present in CD4+ human peripheral blood T cells. Cell Immunol. 118:1989;285-297.
36. Williams N.S., Englehard V.H. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. J. Immunol. 159:1997;2095-2099.
37. Falkenburg J.H., Walfelman A.R., Joosten P., Smit W.M., van Bergen C.A., Bongaerts R.et al. Complete remission of accelerated phase chronic myeloid leukemia-reactive cytotoxic T lymphocytes. Blood. 94:1999;1201-1208.
38. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., Brugger B. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 96:2000;3102-3108.
39. Choudhury B.A., Liang J.C., Thomas E.K., Flores-Romo L., Xie Q., Agusala K.et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 93:1999;780-786.
40. Harrison B.D., Adams J.A., Briggs M., Brereton M.L., Liu Yin J. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood. 97:2001;2764-2771.
41. Notte M., Willinger T., Erben U., Thie E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood. 97:2001;3138-3145.
42. Parmiani G., Rodolfo M., Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells a critique and reappraisal. Hum. Gene Ther. 11:2000;1269-1275.